Substance / Medication

Pergolide mesylate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
[Cutaneous vasculitis during pergolide mesylate treatment].
Serratrice J, Granel B, Disdier P et al. · Rev Med Interne · 2002
PMID: 12378837Case Report
[Sleep attacks and pergolide mesylate].
García Ruiz P J, Hernández J, Cantarero S et al. · Neurologia · 2001
PMID: 11257938Case Report
Pergolide mesylate administration does not decrease blood thyroid hormone concentrations and thyroid function in horses.
Jargielo Martyna M, Kritchevsky Janice E, Bertin François-René · Am J Vet Res · 2024
PMID: 39626361Other
Pharmacokinetic properties of pergolide mesylate following single and multiple-dose administration in donkeys (Equus asinus).
Xue Cynthia, Davis Jennifer, Berghaus Londa J et al. · Equine Vet J · 2023
PMID: 36572900Other
Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
Rendle D I, Doran G, Ireland J et al. · Domest Anim Endocrinol · 2019
PMID: 31082785Preclinical
Effects of pergolide mesylate on transduction efficiency of PEP-1-catalase protein.
Sohn Eun Jeong, Kim Dae Won, Kim Young Nam et al. · Biochem Biophys Res Commun · 2011
PMID: 21324306Preclinical
Single-dose oral pharmacokinetics of pergolide mesylate in healthy adult mares.
Gehring Ronette, Beard Laurie, Wright Abra et al. · Vet Ther · 2010
PMID: 20949429Preclinical
Multitemperature stability and degradation characteristics of pergolide mesylate oral liquid.
Shank Brandon R, Ofner Clyde M · J Pharm Pract · 2010
PMID: 21507864Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pergolide mesilate (substance)
SNOMED CT
108469007
UMLS CUI
C0031008

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.